A Bayesian adaptive phase I/II clinical trial design with late-onset competing risk outcomes

A Bayesian adaptive phase I/II clinical trial design with late-onset competing risk outcomes

Early-phase dose-finding clinical trials are often subject to the issue of late-onset outcomes. In phase I/II clinical trials, the issue becomes more intractable because toxicity and efficacy can be competing risk outcomes such that the occurrence of the first outcome will terminate the other one. I...

Full description

Bibliographic Details
Main Authors: Cao, S. (Author), Jin, I.H (Author), Zang, Y. (Author), Zhang, C. (Author), Zhang, Y. (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2021
Subjects:
adaptive design
algorithm
Bayes theorem
Bayes Theorem
Bayesian analysis
clinical trial
clinical trial (topic)
Clinical Trials as Topic
competing risk
computer simulation
Computer Simulation
design
dose response
Dose-Response Relationship, Drug
human
Humans
late-onset
methodology
phase 1 clinical trial
phase 2 clinical trial
Phase I/II clinical trial
Research Design
risk factor
simulation
targeted therapy
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items